News & Updates

Can dapagliflozin be continued in patients with COVID-19?

24 Jun 2021 by

The SGLT2 inhibitor dapagliflozin did not result in a reduced incidence of organ failure or death in patients with cardiometabolic risk factors who were hospitalized with COVID-19, according to the phase III DARE-19* trial. However, this finding does not support discontinuation of SGLT2 inhibitors in COVID-19 patients.

Can dapagliflozin be continued in patients with COVID-19?

24 Jun 2021

Ravidasvir boosts hepatitis C elimination

24 Jun 2021 by

Malaysia is the first country in the world to approve ravidasvir as treatment for chronic hepatitis C virus (HCV) infection.

Ravidasvir boosts hepatitis C elimination

24 Jun 2021

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

24 Jun 2021 by

The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

24 Jun 2021

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021 by

Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021

‘Sporebiotics’ reduce FD symptoms

23 Jun 2021 by

Spore-forming probiotics, otherwise termed “sporebiotics”, may help reduce post-prandial gastrointestinal (GI) symptoms such as bloating and epigastric pain in individuals with functional dyspepsia (FD), says an expert at DDW 2021.

‘Sporebiotics’ reduce FD symptoms

23 Jun 2021

Aspirin in ASCVD: Baby dose as good as high dose?

23 Jun 2021 by

Taking low-strength aspirin at 81 mg dose daily (also known as baby aspirin) appeared to be as effective as a higher dose of 325 mg for secondary prevention in people with established atherosclerotic cardiovascular disease (ASCVD), with no difference in major bleeding outcomes, according to the ADAPTABLE* trial presented at ACC.21.

Aspirin in ASCVD: Baby dose as good as high dose?

23 Jun 2021

Sapanisertib-based combo beneficial to postmenopausal women with pretreated breast cancer

23 Jun 2021

In postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer, use of sapanisertib plus exemestane or fulvestrant is safe and associated with promising clinical activity, according to the results of a phase IB/II trial.

Sapanisertib-based combo beneficial to postmenopausal women with pretreated breast cancer

23 Jun 2021

Semaglutide on top of ESG boosts weight loss in diabetes

23 Jun 2021 by

Once-weekly injection of the GLP-1* agonist semaglutide, on top of endoscopic sleeve gastroplasty (ESG), led to a greater weight loss and better glucose control vs ESG alone in patients with diabetes and excess weight but are not candidates for bariatric surgery, a new study has shown.

Semaglutide on top of ESG boosts weight loss in diabetes

23 Jun 2021

TEOS framework improves operational definitions of medication adherence in research

23 Jun 2021 by

When designing a medication adherence research and reporting on these components, measurement quality can be improved with the use of the Timelines-Events-Objectives-Sources (TEOS) framework, suggests a study.

TEOS framework improves operational definitions of medication adherence in research

23 Jun 2021

Intense ADT tied to positive pathologic responses in prostate cancer

23 Jun 2021

Intense neoadjuvant hormone therapy in high-risk localized prostate cancer is associated with favourable pathologic responses (tumour <5 mm) in nearly one of five patients, a phase II study has shown. In addition, pathologic responses are comparable between treatment groups.

Intense ADT tied to positive pathologic responses in prostate cancer

23 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Can dapagliflozin be continued in patients with COVID-19?

Can dapagliflozin be continued in patients with COVID-19?

Ravidasvir boosts hepatitis C elimination

Ravidasvir boosts hepatitis C elimination

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

‘Sporebiotics’ reduce FD symptoms

‘Sporebiotics’ reduce FD symptoms

Aspirin in ASCVD: Baby dose as good as high dose?

Aspirin in ASCVD: Baby dose as good as high dose?

Sapanisertib-based combo beneficial to postmenopausal women with pretreated breast cancer

Sapanisertib-based combo beneficial to postmenopausal women with pretreated breast cancer

Semaglutide on top of ESG boosts weight loss in diabetes

Semaglutide on top of ESG boosts weight loss in diabetes

TEOS framework improves operational definitions of medication adherence in research

TEOS framework improves operational definitions of medication adherence in research

Intense ADT tied to positive pathologic responses in prostate cancer

Intense ADT tied to positive pathologic responses in prostate cancer